Phaseline

Companies › ImmunityBio

ImmunityBio: clinical trials, targets and expected readouts

9 active drug programs in 35 registered trials: 22 Phase 2, 12 Phase 1, 1 Phase 3; Oncology, Infectious disease; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nogapendekin Alfa Inbakicept (N803)
Interleukin-15 receptor agonist
IL2RG, IL2RB, IL15RAPhase 3NSCLC Stage IV; Long COVID; Platinum-resistant Ovarian Cancer; Relapsed B-Cell Non Hodgkin Lymphoma …Mar 2027
M-CENK
Autologous engineered NK cells
–Phase 2Platinum-resistant Ovarian Cancer; Metastatic Solid TumorMay 2027
CD19 t-haNK
CAR-T cell therapy targeting CD19
CD19Phase 2Relapsed B-Cell Non Hodgkin LymphomaMay 2027
Aldoxorubicin
DNA topoisomerase II alpha inhibitor
TOP2APhase 2Pancreatic CancerMay 2027
PD-L1 t-haNK
PD-L1-targeted human aNK cell therapy
CD274, PDCD1LG1Phase 2Pancreatic Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Head and Neck CancerMay 2027
CD19t-haNK suspension
CAR-T cell therapy targeting CD19; engineered NK-92 cell line expressing CD19-directed CAR
CD19Phase 1Non Hodgkin's Lymphoma Refractory/RelapsedMar 2027
IBRX-042
hAd5-based oncolytic virus expressing HPV E6 and E7 epitopes
–Phase 1HPV-Related CarcinomaSep 2027
Rituximab (CD19)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 1Non-Hodgkin Lymphoma Refractory/ RelapsedOct 2027
Intravesical Recombinant Mycobacterium (rMBCG)
Live attenuated Mycobacterium bovis BCG strain expressing recombinant immunomodulatory pro
–Phase 1NMIBCFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04505501Nogapendekin Alfa Inbakicept (N803)Phase 2HIV/AIDSInfectious diseaseJun 2025
NCT07108036Nogapendekin Alfa Inbakicept (N803)Phase 2Long COVIDInfectious diseaseOct 2026
NCT06161545Nogapendekin Alfa Inbakicept (N803)Phase 2Stage II Squamous Cell Carcinoma of the Head and NeckOncologyDec 2026
NCT04340596Nogapendekin Alfa Inbakicept (N803)Phase 1HIV InfectionInfectious diseaseDec 2026
NCT06239220Nogapendekin Alfa Inbakicept (N803)Phase 2Head and Neck CancerOncologyDec 2026
NCT06253494Nogapendekin Alfa Inbakicept (N803)Phase 1Endometrial CancerOncologyDec 2026
NCT06239220PD-L1 t-haNKPhase 2Head and Neck CancerOncologyDec 2026
NCT05618925CD19t-haNK suspensionPhase 1Non Hodgkin's Lymphoma Refractory/RelapsedOncologyMar 2027
NCT07123727Nogapendekin Alfa Inbakicept (N803)Phase 2Long COVIDInfectious diseaseMar 2027
NCT05618925Nogapendekin Alfa Inbakicept (N803)Phase 1Non Hodgkin's Lymphoma Refractory/RelapsedOncologyMar 2027
NCT06710288Nogapendekin Alfa Inbakicept (N803)Phase 2Platinum-resistant Ovarian CancerOncologyMay 2027
NCT06710288M-CENKPhase 2Platinum-resistant Ovarian CancerOncologyMay 2027
NCT07125872Nogapendekin Alfa Inbakicept (N803)Phase 2Relapsed B-Cell Non Hodgkin LymphomaOncologyMay 2027
NCT07125872CD19 t-haNKPhase 2Relapsed B-Cell Non Hodgkin LymphomaOncologyMay 2027
NCT04390399Nogapendekin Alfa Inbakicept (N803)Phase 2Pancreatic CancerOncologyMay 2027
NCT04898543Nogapendekin Alfa Inbakicept (N803)Phase 1Metastatic Solid TumorOncologyMay 2027
NCT04898543M-CENKPhase 1Metastatic Solid TumorOncologyMay 2027
NCT04390399AldoxorubicinPhase 2Pancreatic CancerOncologyMay 2027
NCT04390399PD-L1 t-haNKPhase 2Pancreatic CancerOncologyMay 2027
NCT05419011Nogapendekin Alfa Inbakicept (N803)Phase 2Colorectal CarcinomaOncologyJul 2027
NCT05976828IBRX-042Phase 1HPV-Related CarcinomaOncologySep 2027
NCT06334991Rituximab (CD19)Phase 1Non-Hodgkin Lymphoma Refractory/ RelapsedOncologyOct 2027
NCT06149481Nogapendekin Alfa Inbakicept (N803)Phase 1Metastatic Colorectal CancerOncologyOct 2027
NCT07085338Nogapendekin Alfa Inbakicept (N803)Phase 2Neuroblastoma RecurrentOncologyFeb 2028
NCT06800963Intravesical Recombinant Mycobacterium (rMBCG)Phase 1NMIBCOncologyFeb 2028
NCT07574541Nogapendekin Alfa Inbakicept (N803)Phase 2AdenocarcinomaOncologyJun 2028
NCT06745908Nogapendekin Alfa Inbakicept (N803)Phase 3NSCLC Stage IVOncologySep 2028
NCT07686380Nogapendekin Alfa Inbakicept (N803)Phase 2Recurrent Prostate CancerOncologyJan 2029
NCT03022825Nogapendekin Alfa Inbakicept (N803)Phase 2Bladder CancerOncologyMar 2029
NCT03228667Nogapendekin Alfa Inbakicept (N803)Phase 2Non-Small Cell Lung CancerOncologyAug 2029
NCT03228667PD-L1 t-haNKPhase 2Non-Small Cell Lung CancerOncologyAug 2029
NCT06061809Nogapendekin Alfa Inbakicept (N803)Phase 2GlioblastomaOncologyDec 2029
NCT06061809PD-L1 t-haNKPhase 2GlioblastomaOncologyDec 2029
NCT07355205Nogapendekin Alfa Inbakicept (N803)Phase 1Non-small Cell Lung Cancer Stage IVOncologyJul 2032
NCT02138734Nogapendekin Alfa Inbakicept (N803)Phase 1Non-muscle Invasive Bladder CancerOncologyMar 2039

From the company's SEC filings

Cash and short-term investments of $334m on 2026-09-30; operating cash outflow about $291m a year; runway about 14 months at that burn, to Nov 2027; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (2) IL2RG (1) IL2RB (1) IL15RA (1) MS4A1 (1) TOP2A (1) CD274 (1) PDCD1LG1 (1)

Companies with the same targets

Roche Bristol-Myers Squibb Gilead Sciences Chongqing Precision Biotech Sanofi Allogene Therapeutics Amgen AstraZeneca Miltenyi Biomedicine Beijing Yongtai Ruike Biotechnology Company

Companies built like this

Replimune Fate Therapeutics Arcus Biosciences BioNTech SE Eikon Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.